Insulet Corp

Insulet Corp Stock Forecast & Price Prediction

Live Insulet Corp Stock (PODD) Price
$235.61

17

Ratings

  • Buy 10
  • Hold 7
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$235.61

P/E Ratio

41.87

Volume Traded Today

$385,300

Dividend

Dividends not available for PODD

52 Week High/low

243.98/151.56

Insulet Corp Market Cap

$16.23B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $PODD ๐Ÿ›‘

Before you buy PODD you'll want to see this list of ten stocks that have huge potential. Want to see if PODD made the cut? Enter your email below

PODD Summary

Based on ratings from 17 stock analysts, the Insulet Corp stock price is expected to increase by 5.11% in 12 months. This is calculated by using the average 12-month stock price forecast for Insulet Corp. The lowest target is $185 and the highest is $285. Please note analyst price targets are not guaranteed and could be missed completely.

PODD Analyst Ratings

PODD is a stock in Healthcare which has been forecasted to be worth $247.64 as an average. On the higher end, the forecast price is $285 USD by Jayson Bedford from Raymond James and on the lower end PODD is forecasted to be $185 by from SVB Leerink.

PODD stock forecast by analyst

These are the latest 20 analyst ratings of PODD.

Analyst/Firm

Rating

Price Target

Change

Date

Marie Thibault
BTIG

Buy

$260

Maintains

Oct 14, 2024
Jayson Bedford
Raymond James

Outperform

$260

Maintains

Oct 14, 2024
Joanne Wuensch
Citigroup

Buy

$275

Maintains

Oct 1, 2024
William Plovanic
Canaccord Genuity

Buy

$269

Maintains

Sep 25, 2024
Matt O'Brien
Piper Sandler

Overweight

$285

Maintains

Sep 17, 2024
Matt Miksic
Barclays

Equal-Weight

$220

Maintains

Aug 12, 2024
Matthew Taylor
UBS

Neutral

$223

Maintains

Aug 9, 2024
Marie Thibault
BTIG

Buy

$250

Maintains

Aug 9, 2024
William Plovanic
Canaccord Genuity

Buy

$234

Maintains

Jul 23, 2024

OTR Global

Mixed


Downgrade

Jun 10, 2024
Issie Kirby
Redburn Atlantic

Buy

$235

Initiates

May 30, 2024
Matt Miksic
Barclays

Equal-Weight

$200

Maintains

May 13, 2024
Matthew Taylor
Jefferies

Buy

$260

Maintains

May 10, 2024
Jayson Bedford
Raymond James

Outperform

$213

Maintains

May 10, 2024
Kyle Rose
Canaccord Genuity

Buy

$234

Maintains

May 10, 2024
Mike Polark
Wolfe Research

Outperform

$200

Upgrade

May 7, 2024
Matt Miksic
Barclays

Equal-Weight

$213

Maintains

Feb 26, 2024
Matt O'Brien
Piper Sandler

Overweight

$230

Maintains

Feb 23, 2024
Robbie Marcus
JP Morgan

Overweight

$225

Maintains

Feb 23, 2024
Mathew Blackman
Stifel

Hold

$208

Maintains

Feb 5, 2024

PODD Company Information

What They Do: Develops insulin delivery systems for diabetes.

Business Model: The company generates revenue by designing, manufacturing, and selling innovative insulin delivery systems, particularly through its Omnipod platform. Its products are marketed primarily via independent distributors, pharmacy channels, and direct sales in various regions including the U.S., Canada, and Europe.

Other Information: Founded in 2000 and headquartered in Acton, Massachusetts, Insulet Corporation focuses on enhancing diabetes management through technology, including automated insulin delivery and integration with continuous glucose monitors.
PODD
Insulet Corp (PODD)

When did it IPO

2007

Staff Count

3,000

Country

United States

Sector/Industry

Healthcare/Medical Devices

CEO

Dr. James R. Hollingshead Ph.D.

Market Cap

$16.23B

Insulet Corp (PODD) Financial Data

In 2023, PODD generated $1.70B in revenue, which was a increase of 30.02% from the previous year. This can be seen as a signal that PODD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$904.4M

Revenue From 2021

$1.10B

21.49 %
From Previous Year

Revenue From 2022

$1.31B

18.79 %
From Previous Year

Revenue From 2023

$1.70B

30.02 %
From Previous Year
  • Revenue TTM $1.87B
  • Operating Margin TTM 11.2%
  • Gross profit TTM $1.16B
  • Return on assets TTM 6.8%
  • Return on equity TTM 50.9%
  • Profit Margin 21.1%
  • Book Value Per Share 14.24%
  • Market capitalisation $16.23B
  • Revenue for 2021 $1.10B
  • Revenue for 2022 $1.31B
  • Revenue for 2023 $1.70B
  • EPS this year (TTM) $5.53

Insulet Corp (PODD) Latest News

News Image

Thu, 31 Oct 2024

Sentiment - NEUTRAL

Source - Zacks Investment Research

Summary - Insulet (PODD) is not expected to meet the criteria for a potential earnings beat in its upcoming report, according to key expectations outlined.

Why It Matters - Insulet's potential earnings miss could negatively impact its stock price, indicating weakness in performance and affecting investor confidence in future growth prospects.

News Image

Fri, 01 Nov 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Insulet Corporation (NASDAQ: PODD) will celebrate National Diabetes Awareness Month and World Diabetes Day in November with various activities to support diabetes management.

Why It Matters - Insulet's announcement highlights its commitment to diabetes awareness, potentially enhancing brand loyalty and market position, which can positively impact stock performance and investor sentiment.

News Image

Tue, 29 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Insulet Corporation released the Omnipod 5 App for iPhone, enabling full control of its Automated Insulin Delivery System. The app is available for free on the Apple App Store.

Why It Matters - The launch of the Omnipod 5 App enhances Insulet's product ecosystem, potentially increasing user adoption and sales, positively impacting revenue and stock performance.

News Image

Wed, 23 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - PODD is expanding the market for its Omnipod 5 product and maintains strong solvency, indicating financial stability.

Why It Matters - PODD's market expansion and strong solvency suggest growth potential and stability, indicating a favorable environment for investment and future profitability.

News Image

Tue, 22 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Phibro Animal Health (PAHC) and Insulet (PODD) are two Medical - Products stocks of interest to investors. A comparison for value investment potential is suggested.

Why It Matters - The comparison between Phibro Animal Health and Insulet highlights potential investment opportunities, influencing stock selection strategies and impacting portfolio performance.

News Image

Mon, 21 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - NVIDIA, Insulet, and Monolithic Power Systems are identified as top investment picks due to their high net income ratios.

Why It Matters - High net income ratios for NVIDIA, Insulet, and Monolithic Power Systems indicate strong profitability, signaling potential for growth and investment returns.

...

PODD Frequently asked questions

The highest forecasted price for PODD is $285 from Jayson Bedford at Raymond James.

The lowest forecasted price for PODD is $185 from from SVB Leerink

The PODD analyst ratings consensus are 10 buy ratings, 7 hold ratings, and 0 sell ratings.